You are here

Longevity Bulletin: Antimicrobial resistance (Issue 8)

This Longevity Bulletin examines the clinical implications, impact on longevity and the potential economic cost of current trends in AMR.

Antibiotics are one of the most important therapeutic discoveries in medical history. They have revolutionised the way we treat patients with bacterial infections and have contributed to reducing mortality and morbidity from bacterial diseases.

Unfortunately, antibiotics have been liable to misuse. They are often unnecessarily prescribed for viral infections, against which they have no effect. In the Longevity Bulletin, Professor Dame Sally Davies, Chief Medical Officer for England, states that the world is already seeing the consequence of AMR with estimates of around 50,000 deaths per year recently in Europe and the US. Furthermore, drug-resistant infections are estimated to cause 10 million deaths a year and cost up to £66 trillion by 2050.

This edition of the Longevity Bulletin considers potential impacts of AMR on society and demonstrates real collaboration between a number of professions.

Download the Longevity Bulletin: Antimicrobial Resistance

To further develop the understanding of AMR and the risk associated consequences, the IFoA organised a seminar with some of the Longevity Bulletin’s contributors. This event included a number of presentations and panel discussion.

The video recording is now available to watch on our YouTube channel or VLE. Members should view the video on the VLE to enable CPD to be verified.

 

Related documents

Contact Details

For more information about the Longevity Bulletin or to subscribe please contact the Research and Knowledge Team.

research@actuaries.org.uk

Filter or search events

Start date
E.g., 04/03/2021
End date
E.g., 04/03/2021

Events calendar

  • Finance in the Public Interest Series

    16 March 2021 - 23 March 2021

    Spaces available

    There is widening debate that many of our social, financial and regulatory institutions need to be rethought so that we can create more sustainable futures, particularly in light of the Covid-19 pandemic, the policy/macro-economic response to the pandemic and how it affects consumers, as well as the impending climate crisis. This multi-day series of three keynote webinars, individually presented by leading economist John Kay, Sir Paul Collier, Professor of Economics and Public Policy at the Blavatnik School of Government, Ashok Gupta, Chair at Mercer Ltd, and Nico Aspinall, Chief Investment Officer at B&CE, will open up discussion on these essential topics. The series will culminate in a panel session with Chief Economist of the Bank of England, Andy Haldane.

  • The price is righter

    16 March 2021

    Spaces available

    This webinar provides an overview of the state of the UK protection market, and how different insurers are using different levels of sophistication to price (such as using customer demand models). It considers how insurers have implemented these sophisticated pricing techniques, and the practical challenges they have faced.

  • Spaces available

    This discussion will revolve around the latest industry developments including and introduction to Part VII transfers and Schemes of Arrangement (process, parties involved and recent events), insights and lessons from recent with-profits transactions and restructurings (including Equitable Life and Pru-Rothesay), how firms can apply these learnings to future arrangements, and the outlook for future with-profits transactions and restructurings (including the impacts of Covid-19 and Brexit)

     

  • Spaces available

    What is stewardship and how has the landscape changed under the 2020 UK Stewardship Code? How does effective stewardship create long term value for beneficiaries and what roles do asset owners and asset managers play in active stewardship. This webinar will offer answers to these questions in a practical approach to stewardship reporting.

  • Spaces available

    Mis-estimation risk is a key element of demographic risk, and past work has focused on mis-estimation risk on a run-off basis.  However, this does not meet the requirements of regulatory regimes like Solvency II, which demands that capital requirements are set through the prism of a finite horizon like one year.  This paper presents a value-at-risk approach to mis-estimation risk suitable for Solvency II work.